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grafts, angioplasty, haemodialysis and diabetes were
“lumped” together for analysis. We re-evaluated the data
by meta-analysing sub-groups of trials according to the
risk factor of the patient population (where there was
more than one trial for the risk factor). RESULTS: The
Relative Risk Reductions with [95% CI] for DP + ASA
compared to ASA alone for all types of patients was cal-
culated to be 5% [-5 to 15%]. However the RRRs were
diverse when trial patient populations were split for
analysis. RRRs ranged from 15% [4% to 26%] for
patients with previous Stroke/TIA to -19% [-62% to
12%] for patients who had had CABG previous to enter-
ing the study. CONCLUSIONS: The usefulness of the
ATC’s summary statistics in decision-making for speciﬁc
patient populations is limited, due to heterogeneous
patient populations being combined together. In particu-
lar, our sub-group analysis revealed a statistically signiﬁ-
cant RRR in vascular events for patients treated with DP
+ ASA compared to ASA amongst patients with previous
TIA/stroke.
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OBJECTIVE: Various representations of uncertainty in
cost effectiveness analysis alongside a randomized trial
have been suggested. Due to its informational richness the
cost acceptability curve has been favored. Alternative rep-
resentations of uncertainty are conﬁdence intervals and
bootstrap distribution in the c/e plane. If the difference in
effects is small different problems arise with either of the
methods. Aspects of using the different presentations of
uncertainty for decision making are discussed for the
study example. METHODS: Methods compared included
cost-effectiveness acceptability curve bootstrap conﬁ-
dence intervals and bootstrap scatter plots focusing on
their user-friendliness, informational richness and guid-
ance for decision making. Data came from an economic
evaluation in the rehabilitation of low back patients that
has been performed in two German rehabilitation centers.
Treatment in the standard arm consisted of a multimodal
program including physiotherapy and educational mea-
sures. The experimental group received additional psy-
chological treatment. RESULTS: The cost effectiveness
acceptability curve intersecting at 0.61 showed a small
slope. The bootstrap conﬁdence interval ranged from €1.4
million to €-20.000 covering points in all quadrants.
61% of the bootstrap replicates where in the southeast
quadrant indicating dominance. CONCLUSIONS: Sug-
gestions are made for further discussion of using uncer-
tain results for decision making as a conservative rule for
a risk-neutral decision maker, it is suggested that a 50%
probability of the intervention being dominant (as found
in the study) may not be used to reject it on economic
grounds.
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OBJECTIVE: Assessment of patient preferences for
attributes of asthma treatments. METHODS: Two
hundred ninety-eight patients, aged 18–60, from 15
centres in Sweden completed a questionnaire concern-
ing their asthma and ranked 18 alternative treatments
using conjoint analysis. Patients were treated with either
inhaled corticosteroids (ICS) or short acting bron-
chodilator alone (n = 123) or ICS and long acting bron-
chodilator (separate inhalers n = 87, combination inhaler
n = 88). Attributes analysed were: maintenance treatment,
additional reliever, time to onset and duration of reliever,
number of symptom-free days (SFD) per month, and out-
of-pocket cost per month. RESULTS: Conjoint analysis
showed that the most important aspect of treatment was
SFD. Forty percent of the patients had 15 or less SFD per
month. Eighty-ﬁve percent of the patients preferred
another treatment than their current treatment. Treat-
ment preferences were heterogeneous and in 78% not
covered by current treatment guidelines. One of two
patients preferred a combination inhaler to separate
inhalers, and three of four patients a reliever that is both
rapid- and long-acting. The most preferred treatment was
a combination inhaler for maintenance and reliever use.
On average, the patients were willing to pay SEK 328
(USD $36), additionally to their current expenditure, per
month for the change to the preferred treatment. CON-
CLUSION: Symptom-free days were the most important
attribute in asthma treatment. Patients were willing to
pay for a switch to their preferred treatment. The most
favoured treatments were a reliever therapy that is both
rapid- and long acting and a combination inhaler for both
maintenance and as needed use.
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OBJECTIVES: To develop a quantitative algorithm 
that transforms the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS), which is the most frequently used 
instrument to evaluate different clinical dimensions of
Parkinson’s Disease (PD), into EuroQoL (EQ-5D) values.
METHODS: A total of 157 PD patients (mean age: 
67yrs., 63% male, mean total UPDRS: 44, mean EQ-5D:
0.74) were recruited in a prospective study at a German
movement disorders center. Both EQ-5D and UPDRS
were evaluated at baseline in 124 patients. Spearman cor-
relation coefﬁcient (R) was used to test whether total
UPDRS score, sub scores (U2,U3,U4), and other patient
characteristics were univariately associated with EQ-5D.
A transformation algorithm with UPDRS sub scores as
predictors and EQ-5D as outcome was derived using mul-
tivariate regression analysis. Goodness-of-ﬁt was deter-
mined by adjusted R-square and the Hosmer-Lemeshow
method. RESULTS: In the univariate analysis, all UDPRS
sub scores were signiﬁcantly (p < 0.05) correlated with
clinical stage on the Hoehn & Yahr (HY) scale. Signiﬁ-
cant inverse correlation (all p < 0.001) was found between
EQ-5D and total UPDRS (R = -0.67), U2 (R = -0.63),
U3 (R = -0.60), U4 (R = -0.59), and HY stage (R =
-0.52). Multivariate analysis showed that 52% of the
variance in EQ-5D could be explained by the following
equation: EQ-5D = (99.62 - 1.36 ¥ U2 - 0.13 ¥ U3 -
1.66 ¥ U4)/100. The Hosmer-Lemeshow test showed
good predictive power. Using different mathematical
functions (e.g., log, logit, square) of predictors, utilities
or disutilities, and inclusion of interaction terms did not
substantially increase adjusted R-square. CONCLU-
SIONS: We suggest a simple, parsimonious, and easily
feasible algorithm for the transformation of UPDRS
scores into EQ-5D-based utilities. The purpose of this
function is not to predict individual quality of life, but
mean utilities for populations with a speciﬁc UPDRS 
conﬁguration, which may be used in the evaluation of
intervention’s overall effectiveness or cost-effectiveness.
This algorithm can be applied to existing UPDRS data
sets and used in cost-utility analyses of health technolo-
gies.
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OBJECTIVE: To measure the maximum willingness to
pay (WTP) for a hearing aid (HA) in the Netherlands in
both hard of hearing persons and persons accompanying
them. METHODS: In a survey 151 clients and 55 persons
accompanying them were asked about their maximum
WTP for a HA, the out of pocket (OoP) payment for the
HA(s) currently ﬁtted, and some perceptions about the
reimbursement of HAs, when visiting their HA dispenser.
RESULTS: The mean age of the clients was 70 years, and
of the accompanying persons 62 years. In both groups
approximately 50% was male, 20% earned an income
below €1150 and 7% an income above €3400, and two
third were compulsory insured. Most accompanying
persons were either the partner (63%) or a child (24%)
of the client. The mean OoP payment for the current
HA(s) ﬁtted was €461 (sd 392) per HA. Of both the
clients and the accompanying persons 46% found it
unjust to some extent to pay any OoP contribution for a
hearing aid. Over 90% of the clients and the accom-
panying persons perceived that abolition of the reim-
bursement would be very problematic. Mean maximum
WTP per HA was €277 (sd 296) for the clients and €207
(sd 264) for the accompanying persons. CONCLUSION:
It can be concluded that there is considerable aversion to
an increase of OoP payments as a result of the abolition
of the reimbursement. Mean maximum WTP found in
this study is considerably lower than the ﬁgure observed
in a US study: $982 per HA (Chisolm & Abrams, 2001).
Mean maximum WTP per HA is also lower than the
actual OoP contribution for the HAs currently ﬁtted. This
might reﬂects the difference between revealed and stated
preferences, or may be a result of shifted preference.
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OBJECTIVE: The Vaizey score is a tool to assess the
severity of faecal incontinence and to determine treatment
effect. As clinicians develop the score, it may not reﬂect
the overall health impact of faecal incontinence. This
study investigates the association between the Vaizey
score and health-related utility before patients received
treatment. METHODS: Baseline data from a prospective
diagnostic cohort study were used to evaluate the incon-
tinence score and the health utility of patients. The Vaizey
score (0 (continent)—24 (totally incontinent)) consists 
of items concerning the type (solid, liquid, gas) and 
frequency of faecal incontinence, the use of pads and 
constipating medication, and the amount of social inval-
idation. Health utility was calculated by a simple additive
model using EuroQol5D data on mobility, self-care, daily
activities, pain/discomfort and anxiety/depression.
RESULTS: Data from 89 (13 men; mean age 59) patients
were analysed. On average, patients suffered from incon-
tinence for 8.7 years, the mean Vaizey score was 18.5 and
mean utility 0.82. Lower Vaizey scores coincided with
higher health utility values (Spearman’sr = -0.316, p <
0.01). Patients indicating any problems on a EuroQol
dimension showed higher Vaizey scores than patients
without problems; however, this was only signiﬁcant for
daily activities (Mann-Whitney U = 597.5 p < 0.001) and
anxiety/depression (Mann-Whitney U = 685, p < 0.05).
CONCLUSION: Before treatment the Vaizey score was
signiﬁcantly correlated with total utility and was associ-
ated with two dimensions of the EuroQol: daily activities
and anxiety/depression. Further studies will investigate
